Scarica l'app Stockscreener
101.14
2.24%
2.22
Dopo l'orario di chiusura:
101.44
0.30
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$98.92
Aprire:
$99.03
Volume 24 ore:
8.98M
Relative Volume:
1.11
Capitalizzazione di mercato:
$140.88B
Reddito:
$16.75B
Utile/perdita netta:
$1.85B
Rapporto P/E:
80.91
EPS:
1.25
Flusso di cassa netto:
$2.37B
1 W Prestazione:
+6.33%
1M Prestazione:
-1.49%
6M Prestazione:
+18.85%
1 anno Prestazione:
+38.72%
Intervallo 1D:
$98.93
$101.67
Intervallo di 1 settimana:
$92.70
$102.37
Portata 52W:
$70.97
$107.17
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Confronta BSX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
101.14 | 140.88B | 16.75B | 1.85B | 2.37B | 1.25 |
|
ABT
Abbott Laboratories
|
129.38 | 224.94B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
361.05 | 132.32B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.30 | 107.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.13 | 41.71B | 5.72B | 4.17B | 259.90M | 6.97 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
Boston Scientific (BSX) Reports Positive Results for FARAPULSE System in Atrial Fibrillation Study | BSX Stock News - GuruFocus
Boston Scientific Analysts Boost Their Forecasts Following Upbeat Results - Benzinga
Global Neuroprosthetics Market Expanding Rapidly at a CAGR of ~13% by 2032 Amid Surge in Demand for Advanced Neurological Treatments | DelveInsight - GlobeNewswire Inc.
RBC Capital lifts Boston Scientific stock target to $120 - Investing.com
Boston Scientific (BSX) Price Target Raised to $117 by Truist Analyst | BSX Stock News - GuruFocus
Canaccord maintains Buy rating on Boston Scientific stock - Investing.com
Raymond James Adjusts Boston Scientific (BSX) Price Target, Reaffirms Strong Buy | BSX Stock News - GuruFocus
Boston Scientific (BSX) Price Target Raised by Baird Amid Strong Q1 Performance | BSX Stock News - GuruFocus
Boston Scientific Corporation (NYSE:BSX) Q1 2025 Earnings Call Transcript - Insider Monkey
Canaccord maintains Buy rating on Boston Scientific stock By Investing.com - Investing.com UK
Boston Scientific Stock (BSX): Solid Q1 Earnings Growth - Value The Markets
Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals
Boston Scientific Corp (BSX) Q1 2025 Earnings Call Highlights: Strong Growth and Upgraded ... - Yahoo Finance
Boston Scientific Reports Strong Q1 2025 Growth - TipRanks
Boston Scientific Reports Strong Earnings Amid Challenges - TipRanks
Data backs Boston Scientific drug-eluting stent - MassDevice
BTIG Raises Price Target for Boston Scientific (BSX) to $124 Amid Strong Outlook | BSX Stock News - GuruFocus
Why Boston Scientific (BSX) Stock Is Up Today - Yahoo Finance
Hedge Fund and Insider Trading News: Bill Ackman, Robert Charles Gibbins, Dan Loeb, Elliot Management, Lindblad Expeditions Holdings Inc (LIND), Boston Scientific Corp (BSX), and More - Insider Monkey
Boston Scientific says sales could grow up to 17% this year - MassDevice
Boston Scientific Revises 2025 Financial Goals Following Strong Q1 Results - Finimize
Boston Scientific (BSX) Surpasses Q1 Expectations, Raises 2025 Outlook - GuruFocus
Is Boston Scientific Corp. (NYSE:BSX) the Best Stock Under $100 to Buy According to Hedge Funds? - Yahoo Finance
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised - Yahoo Finance
Earnings call transcript: Boston Scientific beats Q1 2025 forecasts - Investing.com
Boston Scientific Stock Surges on Strong Results, Outlook; CFO To Retire - Yahoo Finance
Boston Scientific Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Boston Scientific's Heart Device Success Lifts 2025 Profit Forecast - Finimize
Boston Scientific (BSX) Announces CFO Transition - GuruFocus
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Boston Scientific shares rise on strong Q1 results, raised EPS guidance - Baystreet.ca
Boston Scientific Corporation (BSX) Announces CFO Transition - GuruFocus
Boston Scientific Beats Expectations With Strong Q1 Performance - Finimize
Boston Scientific (BSX) Exceeds Q1 Expectations with Strong Revenue Performance | BSX Stock News - GuruFocus
Boston Scientific: Q1 Earnings Snapshot - News-Times
Boston Scientific Q1 2025 slides: revenue surges 21%, EPS jumps 34% on strong EP growth - Investing.com
Boston Scientific Corp (BSX) Q1 2025 Earnings: Revenue Surpasses - GuruFocus
Boston Scientific (BSX) Announces CFO Transition as Dan Brennan Retires | BSX Stock News - GuruFocus
Boston Scientific CFO Dan Brennan to retire, Jon Monson to succeed - TipRanks
Boston Scientific (BSX) Surpasses Q1 Expectations with Strong Revenue Growth - GuruFocus
Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan - Yahoo Finance
Boston Scientific (NYSE:BSX) Beats Q1 Sales Targets, Next Quarter’s Sales Guidance is Optimistic - Yahoo Finance
Boston Scientific Q1 2025 Financial Results - TradingView
Boston Scientific Corp Q1 Profit Increases, Beats Estimates - Nasdaq
Boston Scientific announces results for first quarter 2025 - Financial Times
Boston Scientific earnings missed by $0.29, revenue fell short of estimates - Investing.com
Boston Scientific’s SVP Brown Vance sells shares for $458,904 - Investing.com
Boston Scientific’s SVP Brown Vance sells shares for $458,904 By Investing.com - Investing.com India
Boston Scientific (BSX) Q1 Earnings Preview: Consistent Outperformance Expected - GuruFocus
Boston Scientific Presses Its Advantage in Pulsed Field Ablation - Morningstar
Earnings Preview: Boston Scientific - Benzinga
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):